Specialty Pharmacy

Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) intended for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Timely access to cancer treatment improves patient outcomes.

The investigators said that there were no new safety signals identified, and no reported instances of tumor lysis syndrome.

As some of the nation’s leading pharmaceutical and biotech giants ramp up product development and commercialization, what was once a futuristic concept has become a reality.

Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.

Pyrotinib combined with capecitabine found to improve overall survival in patients with previously treated HER2-positive metastatic breast cancer.

Rylaze is a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.

In the case reviewed, the pharmacy department created an interdisciplinary Biosimilar Task Force responsible for making decisions relating to the adoption of biosimilar therapies.

Pharmacy leaders can be equipped to make effective decisions to support a successful work experience, regardless of work setting.

FDA approves rituximab (Rituxan) plus chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.

Ibrutinib in combination with venetoclax shows promise in patients with previously untreated chronic lymphocytic leukemia.

Affordability in drug pricing can be addressed by bringing the manufacturer and plan sponsor to negotiate costs and determine fair compensation for product and service providers in the supply chain.

The diagnostic tool widens the age group of individuals who can get tested and can be used in conjunction with a mammogram.

Approximately half of people with HCV don't know they're infected, mainly because they have no symptoms.

Although specialty therapies have the potential to help people live healthier lives, their cost and complexity can create distinct challenges.

Miglustat (Zavesca) is indicated for the treatment of mild to moderate type I Gaucher disease.

Chronic HBV increases the risk of developing liver failure, liver cancer, and cirrhosis.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, provides an analysis and overview of key specialty pharmaceuticals in development.

Lomecel-B (Longeveron) is an investigational allogeneic, bone marrow-derived medicinal signaling cell medication that is being evaluated in a phase 2 trial.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, discusses key drugs in development that are slated to launch in 2022.

Ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.

Are you curious about what other pharmacists earn? About the job satisfaction and compensation of pharmacists in other geographic areas? So are we!

Investigators have developed an immunotherapy that is a potential option for children with hard-to-treat brain cancer.

Ten quiz questions to assess your knowledge on common symptoms and treatments for HIV.

The study’s identification of a network of possible candidate genes to carefully control for mutations could alter the future clinical implementation of CRISPR.

The Build Back Better bill include an authorization for the government to negotiate lower drug prices.

Pembrolizumab demonstrated a statistically significant improvement in disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.

Olumiant shows favorable long-term safety profile in rheumatoid arthritis.

Pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments.